Overview

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side effects that might be associated with it.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Methylphenidate
Phenylethyl Alcohol